What is Axsome Therapeutics, Inc's Market Cap?

Axsome Therapeutics, Inc's Market Cap is $7.6B, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's Enterprise Value?

Axsome Therapeutics, Inc's Enterprise Value is $7.5B, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's Price / Sales?

Axsome Therapeutics, Inc's Price / Sales is 9.8×, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's EV / Revenue?

Axsome Therapeutics, Inc's EV / Revenue is 9.6×, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's EV / EBITDA?

Axsome Therapeutics, Inc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's Revenue (TTM)?

Axsome Therapeutics, Inc's Revenue (TTM) is $776.6M, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's Net Income (TTM)?

Axsome Therapeutics, Inc's Net Income (TTM) is -$191.6M, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's EBITDA?

Axsome Therapeutics, Inc's EBITDA is -$179.2M, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's Diluted EPS (TTM)?

Axsome Therapeutics, Inc's Diluted EPS (TTM) is -3.66, based on as-reported figures from SEC (XBRL) filings.

What is Axsome Therapeutics, Inc's EBITDA Margin?

Axsome Therapeutics, Inc's EBITDA Margin is -23.1%, based on as-reported figures from SEC (XBRL) filings.

AKYLA/ Financials

Equity / PHARMACEUTICAL PREPARATIONS

Axsome Therapeutics, Inc

XNAS · usd

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG00B6G7GM6

145.04▼ 11.03 (-7.07%)

As of 2026-10-23

Price / Volume

Valuation

Market Cap
Enterprise Value
Trailing P/E: —
Price / Sales
EV / Revenue
EV / EBITDA

Financial Highlights

Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt

Trading Information

Previous Close: 156.07
Day's Range: 143.90 – 154.74
52-Week Range: 123.50 – 260.19
Volume: 1.6M
Avg Volume: 817.6K

Share Statistics

Shares Outstanding
Employees: 925
Exchange: XNAS
Listed: 2015-11-19

Share count as of August 3, 2026

Axsome Therapeutics, Inc (AXSM) Financial Statements

View

Income Statement

Detail

Standard

Period

Quarterly

Loading Income Statement…

Key questions about Axsome Therapeutics, Inc (AXSM)

What is Axsome Therapeutics, Inc's Market Cap?: Axsome Therapeutics, Inc's Market Cap is $7.6B, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's Enterprise Value?: Axsome Therapeutics, Inc's Enterprise Value is $7.5B, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's Price / Sales?: Axsome Therapeutics, Inc's Price / Sales is 9.8×, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's EV / Revenue?: Axsome Therapeutics, Inc's EV / Revenue is 9.6×, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's EV / EBITDA?: Axsome Therapeutics, Inc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's Revenue (TTM)?: Axsome Therapeutics, Inc's Revenue (TTM) is $776.6M, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's Net Income (TTM)?: Axsome Therapeutics, Inc's Net Income (TTM) is -$191.6M, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's EBITDA?: Axsome Therapeutics, Inc's EBITDA is -$179.2M, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's Diluted EPS (TTM)?: Axsome Therapeutics, Inc's Diluted EPS (TTM) is -3.66, based on as-reported figures from SEC (XBRL) filings.
What is Axsome Therapeutics, Inc's EBITDA Margin?: Axsome Therapeutics, Inc's EBITDA Margin is -23.1%, based on as-reported figures from SEC (XBRL) filings.

Akyla / Financials · AXSMAs-filed SEC (XBRL) data